Rheumatology News

Ongoing research into the disease processes of lupus has yielded an increased number of therapeutic targets, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

Although swollen lymph nodes are often common in rheumatology, they are also a “hallmark” of rare, life-threatening diseases, such as IgG4-related disease and Castleman disease, according to data published in Rheumatology.

An growing therapeutic armamentarium for antineutrophil cytoplasmic antibody-associated vasculitis — including avacopan and azathioprine — is providing rheumatologists with an increasingly robust array of options, according to a presenter.

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

Biosimilars have shown to be just as effective as original brand name medications in treating rheumatoid arthritis, and the former may be more cost-effective for patients.

Glucocorticoids are an effective go-to treatment for giant cell arteritis, but discontinuing them can be difficult, according to a presenter at the 2024 AWIR annual conference.

A multidisciplinary care model can reduce the risk for subsequent fractures among adults hospitalized for a hip fracture, according to findings published in Journal of Bone and Mineral Research.

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.

The FDA has granted fast track designation to a sublingual tablet form of the muscle relaxant cyclobenzaprine hydrochloride for the management of fibromyalgia, according to a press release from the manufacturer.

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.